FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:115-123 July 12, 2007 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Hartge, P. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Some features of breast cancer in women with a BRCA1 mutation suggest that hereditary breast cancer has a poor outcome. We conducted a national population-based study of Israeli women to determine the influence, if any, of a BRCA1 or a BRCA2 mutation on the prognosis in breast cancer.

Methods We obtained data on all incident cases of invasive breast cancer that were diagnosed from January 1, 1987, to December 31, 1988, and recorded in the Israel National Cancer Registry. We requested a paraffin-embedded tumor block or an unstained slide and the corresponding pathological and clinical records for all such cases. DNA extracted from the tumor specimens was analyzed for the three founder mutations in BRCA1 and BRCA2. For each subject, available pathological and oncologic records were reviewed.

Results We were able to retrieve a pathological sample from 1794 of 2514 subjects (71%). Among those women, we obtained medical records for 1545 (86%). A BRCA1 or BRCA2 mutation was identified in 10% of the women who were of Ashkenazi Jewish ancestry. The adjusted hazard ratios for death from breast cancer were not significantly different among mutation carriers and noncarriers (hazard ratio among BRCA1 carriers, 0.76; 95% confidence interval [CI], 0.45 to 1.30; P=0.31; hazard ratio among BRCA2 carriers, 1.31; 95% CI, 0.80 to 2.15; P=0.28). Among women who were treated with chemotherapy, the hazard ratio for death among BRCA1 carriers was 0.48 (95% CI, 0.19 to 1.21; P=0.12).

Conclusions Breast cancer–specific rates of death among Israeli women are similar for carriers of a BRCA founder mutation and noncarriers.

Source Information

From Clalit Health Services, National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion, Haifa, Israel (G.R., S.B.-N., O.B.-G., N.B.-J., H.S.R.); and the Women's College Research Institute, University of Toronto, Toronto (S.Z., S.A.N.).

Address reprint requests to Dr. Rennert at the Clalit Health Services, National Cancer Control Center, Carmel Medical Center, Haifa 34362, Israel, or at rennert{at}tx.technion.ac.il.

Full Text of this Article

Related Letters:

Prognosis of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations
Goodwin P. J., Phillips K.-A., West D. W., Roukos D. H., Rennert G., Narod S.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1555-1556, Oct 11, 2007. Correspondence

This article has been cited by other articles:

• Raskin, L., Lejbkowicz, F., Barnett-Griness, O., Dishon, S., Almog, R., Rennert, G. (2009). BRCA1 Breast Cancer Risk Is Modified by CYP19 Polymorphisms in Ashkenazi Jews. Cancer Epidemiol. Biomarkers Prev. 18: 1617-1623 [Abstract] [Full Text]  
• Heikkinen, T., Karkkainen, H., Aaltonen, K., Milne, R. L., Heikkila, P., Aittomaki, K., Blomqvist, C., Nevanlinna, H. (2009). The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype. Clin. Cancer Res. 15: 3214-3222 [Abstract] [Full Text]  
• Berrington de Gonzalez, A., Berg, C. D., Visvanathan, K., Robson, M. (2009). Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers. JNCI J Natl Cancer Inst 101: 205-209 [Abstract] [Full Text]  
• Newman, W. G., Hadfield, K. D., Latif, A., Roberts, S. A., Shenton, A., McHague, C., Lalloo, F., Howell, S., Evans, D. G. (2008). Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients. Clin. Cancer Res. 14: 5913-5918 [Abstract] [Full Text]  
• Byrd, L. M., Shenton, A., Maher, E. R., Woodward, E., Belk, R., Lim, C., Lalloo, F., Howell, A., Jayson, G. C., Evans, G. D. (2008). Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiol. Biomarkers Prev. 17: 1535-1542 [Abstract] [Full Text]  
• Briasoulis, E., Ziogas, D., Fatouros, M. (2008). Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers. Ann. Surg. Oncol. 15: 1788-1790 [Full Text]  
• Raskin, L., Pinchev, M., Arad, C., Lejbkowicz, F., Tamir, A., Rennert, H. S., Rennert, G., Gruber, S. B. (2008). FGFR2 Is a Breast Cancer Susceptibility Gene in Jewish and Arab Israeli Populations. Cancer Epidemiol. Biomarkers Prev. 17: 1060-1065 [Abstract] [Full Text]  
• Lykoudis, E., Xeropotamos, N., Ziogas, D., Fatouros, M. (2008). Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?. Ann. Surg. Oncol. 15: 943-944 [Full Text]  
• Theodore, L. (2008). Reexcisions in Breast-Conserving Surgery for Breast Cancer: Can They Be Avoided?. Ann. Surg. Oncol. 15: 945-946 [Full Text]  
• Chetrit, A., Hirsh-Yechezkel, G., Ben-David, Y., Lubin, F., Friedman, E., Sadetzki, S. (2008). Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer. JCO 26: 20-25 [Abstract] [Full Text]  
• Goodwin, P. J., Phillips, K.-A., West, D. W., Roukos, D. H., Rennert, G., Narod, S. (2007). Prognosis of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations. NEJM 357: 1555-1556 [Full Text]  
• Robson, M., Offit, K. (2007). Management of an Inherited Predisposition to Breast Cancer. NEJM 357: 154-162 [Full Text]  
• Hartge, P. (2007). Genes, Cancer Risks, and Clinical Outcomes. NEJM 357: 175-176 [Full Text]  
• (2007). Does Breast Cancer Survival Have a Genetic Basis?. JWatch Women's Health 2007: 3-3 [Full Text]